Susan Krause - Integra LifeSciences Corporate Officer
| IART Stock | USD 21.87 0.04 0.18% |
Executive
Susan Krause is Corporate Officer of Integra LifeSciences Holdings
| Phone | 609 275 0500 |
| Web | https://www.integralife.com |
Integra LifeSciences Management Efficiency
The company has return on total asset (ROA) of 0.0291 % which means that it generated a profit of $0.0291 on every $100 spent on assets. This is way below average. Integra LifeSciences' management efficiency ratios could be used to measure how well Integra LifeSciences manages its routine affairs as well as how well it operates its assets and liabilities.Integra LifeSciences Holdings currently holds 215.38 M in liabilities with Debt to Equity (D/E) ratio of 1.03, which is about average as compared to similar companies. Integra LifeSciences has a current ratio of 3.77, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Integra LifeSciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brian JD | Merit Medical Systems | 64 | |
| Daniel Esq | CONMED | 60 | |
| John Ferrell | CONMED | 56 | |
| Laurie Miller | Haemonetics | 51 | |
| Brian Lloyd | Merit Medical Systems | 63 | |
| Alisha Jerauld | Merit Medical Systems | N/A | |
| Kimberly Lockwood | CONMED | N/A | |
| Mark Butler | Merit Medical Systems | N/A | |
| Jan MD | Haemonetics | N/A | |
| Rajeev Varma | Haemonetics | N/A | |
| Ricardo Alvarez | Merit Medical Systems | N/A | |
| Christian Voigtlander | ICU Medical | 57 | |
| Hollie Foust | CONMED | N/A | |
| JoAnne Alkire | Merit Medical Systems | N/A | |
| Sarah Oliker | CONMED | 43 | |
| Clay Fradd | ICU Medical | N/A | |
| Kerri DiPietro | Haemonetics | N/A | |
| Richard Glaze | CONMED | 59 | |
| Brent Lalomia | CONMED | 49 | |
| Sarah Comstock | Merit Medical Systems | N/A | |
Management Performance
| Return On Equity | -0.0044 | ||||
| Return On Asset | 0.0291 |
Integra LifeSciences Leadership Team
Elected by the shareholders, the Integra LifeSciences' board of directors comprises two types of representatives: Integra LifeSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integra. The board's role is to monitor Integra LifeSciences' management team and ensure that shareholders' interests are well served. Integra LifeSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integra LifeSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Burhop, Chief Scientific Officer, Corporate Vice President | ||
| Ruth Fleming, Vice Marketing | ||
| Eric Schwartz, Corporate Vice President General Counsel, Secretary | ||
| Lea Knight, Executive CFO | ||
| Mathieu Aussermeier, Investor Finance | ||
| Robert Davis, President of Specialty Surgical Solutions and Corporate VP | ||
| Christopher Ward, Senior Relations | ||
| Maria Platsis, Sr Devel | ||
| William Compton, Chief VP | ||
| Chantal VeillonBerteloot, Executive Officer | ||
| Jeffrey Mosebrook, Principal Accounting Officer, Vice President Corporate Controller | ||
| Susan Krause, Corporate Officer | ||
| Stuart Hart, Corporate Officer | ||
| Mark Jesser, Corporate Officer | ||
| Jan Witte, CEO President | ||
| Mojdeh Poul, CEO President | ||
| Laurene Isip, Vice Relations | ||
| Michael McBreen, Executive Surgical | ||
| Carrie Anderson, CFO and Principal Financial Officer, Corporate Vice President | ||
| Eric JD, Chief VP | ||
| Stuart Essig, Chairman of the Board | ||
| Jessica Smith, Corporate Officer | ||
| Stephen Leonard, Corporate Chain |
Integra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Integra LifeSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0044 | ||||
| Return On Asset | 0.0291 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 3.4 B | ||||
| Shares Outstanding | 77.22 M | ||||
| Shares Owned By Insiders | 14.28 % | ||||
| Shares Owned By Institutions | 91.28 % | ||||
| Number Of Shares Shorted | 3.5 M | ||||
| Price To Earning | 26.94 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.